Figure 2.

Overall network of studies in the NMA analysis of UMEC/VI versus LABA/LAMA combination therapies evaluated at 24 weeks for (A) trough FEV₁, (B) SGRQ total score, (C) TDI focal score, and (D) rescue medication use.

Notes: Studies in bold represent those that report only mean values without reporting SE, SD, and 95% CI. Studies DB2113360 and DB2113374 from Decramer et al.⁹ Study DB2113373 from Donohue et al.⁶ Study ZEP117115 from Maleki-Yazdi et al.²⁸

Abbreviations: CI, confidence interval; FEV₁, forced expiratory volume in 1 second; FOR, formoterol; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; NMA, network meta-analysis; PBO, placebo; QVA149, indacaterol/glycopyrronium; SAL, salmeterol; SD, standard deviation; SE, standard error; SGRQ, St George’s Respiratory Questionnaire; TDI, transitional dyspnoea index; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol.